Gentium S.p.A. Announces Submission of a Marketing Authorization Application for Defibrotide to the European Medicines Agency
5/10/2011 10:02:49 AM
VILLA GUARDIA (COMO), Italy, May 10, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced it has submitted a Marketing Authorization Application (MAA), under the centralized licensing procedure, to the European Medicines Agency (EMA) for Defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD) in haematopoietic stem-cell transplantation therapy, in adults and children.
comments powered by